Diffusion-weighted MRI monitoring of pancreatic cancer response to radiofrequency heat-enhanced intratumor chemotherapy.
Diffusion-weighted MRI monitoring of pancreatic cancer response to radiofrequency heat-enhanced intratumor chemotherapy.
复制标题
DOI：
10.1002/nbm.3014
复制
发表时间：
2013-12
影响因子：
2.9
通讯作者：
Yang, Xiaoming
中科院分区：
文献类型：
--
作者：
Zhang, Tong;Zhang, Feng;Meng, Yanfeng;Wang, Han;Le, Thomas;Wei, Baojie;Lee, Donghoon;Willis, Patrick;Shen, Baozhong;Yang, Xiaoming
关键词：
目的探讨磁共振弥散加权成像监测胰腺癌射频热(RFH)强化化疗早期疗效的可行性。分别用磷酸盐缓冲盐水(PBS)、42℃射频消融、吉西他滨、吉西他滨加42°C射频消融治疗不同组的人胰腺癌细胞(PANC-1)和4组24只荷瘤小鼠，分别于治疗前、治疗后1天、1天、7天、14天进行磁共振扩散加权成像和T2加权成像，观察肿瘤的表观扩散系数(ADC)和肿瘤生长情况。MRI表现与肿瘤细胞凋亡分析结果相一致。在体外实验中，定量存活率测定显示，42℃下吉西他滨加射频氢化组的细胞相对存活率低于单纯射频氢化组和吉西他滨组(37%±5%比65%±4%和58%±8%，p<；0.05)。在体内实验中，联合治疗组的相对肿瘤体积小于单纯射频消融组和单纯化疗组(0.82±0.17vs2.23±0.90和1.64±0.44，p=0.003)。体内14T MRI显示，联合治疗组第1天ADC明显减少，第7天和第14天ADC明显增加。联合治疗组细胞凋亡指数明显高于单纯化疗组、射频消融组和PBS组(37%±6%vs20%±5%、8%±2%和3%±1%，p<；0.05)。本研究证实了MRI用于监测射频强化化疗治疗胰腺癌的可行性，为MR/RF联合局部化疗治疗胰腺癌提供了新的选择。
To evaluate the feasibility of using diffusion-weighted MRI to monitor the early response of pancreatic cancers to radiofrequency heat (RFH)-enhanced chemotherapy. Human pancreatic carcinoma cells (PANC-1) in different groups and twenty four mice with pancreatic cancer xenografts in four groups were treated by phosphate buffered saline (PBS) as a control, RFH at 42 °C, gemcitabine and gemcitabine plus RFH at 42°C. One day before and 1, 7, and 14 days after the treatment, diffusion-weighted MR imaging and T2 weighted imaging were applied to monitor the apparent diffusion coefficients (ADCs) of tumors and tumors growth. MRI findings were correlated with results of tumors apoptosis analysis. Of the in vitro experiments, quantitative viability assay showed lower relative cell viabilities treated by gemcitabine plus RFH at 42°C, compared to those by RFH only and gemcitabine only (37% ± 5% vs 65% ± 4% and 58% ± 8%, p < 0.05). Of the in vivo experiments, the combination therapy resulted in smaller relative tumor volume than RFH-only and chemotherapy-only (0.82 ± 0.17 vs 2.23 ± 0.90 and 1.64 ± 0.44, p = 0.003). In vivo 14T MRI demonstrated a remarkable decrease of ADCs at day 1 and increased ADCs at days 7 and 14 in the combination therapy group. The apoptosis index in the combination therapy group was significantly higher than those in the groups of chemotherapy-only, RFH-only and PBS treatments (37% ± 6% vs 20% ± 5%, 8% ± 2%, and 3% ± 1%, p < 0.05). This study confirms that it is feasible to use MRI to monitor RFH-enhanced chemotherapy on pancreatic cancers, which may present new options for efficient treatment of pancreatic malignancies using MR/RF-integrated local chemotherapy.
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
11.2
作者：
Kim H;Morgan DE;Buchsbaum DJ;Zeng H;Grizzle WE;Warram JM;Stockard CR;McNally LR;Long JW;Sellers JC;Forero A;Zinn KR
通讯作者：
Zinn KR
影响因子：
19.7
作者：
Park, Sang Hee;Moon, Woo Kyung;Noh, Dong-Young
通讯作者：
Noh, Dong-Young
DOI：
10.1158/1078-0432.ccr-08-0239
发表时间：
2008-11-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Manning HC;Merchant NB;Foutch AC;Virostko JM;Wyatt SK;Shah C;McKinley ET;Xie J;Mutic NJ;Washington MK;LaFleur B;Tantawy MN;Peterson TE;Ansari MS;Baldwin RM;Rothenberg ML;Bornhop DJ;Gore JC;Coffey RJ
通讯作者：
Coffey RJ
影响因子：
19.7
作者：
Yabuuchi, Hidetake;Hatakenaka, Masamitsu;Honda, Hiroshi
通讯作者：
Honda, Hiroshi